Androgen-deprivation Therapy

intravenous iv drip

Study: Advanced Therapies Underused for First-Line mCSPC Treatment

Most men with metastatic castration-sensitive prostate cancer (mCSPC) in 2018 did not receive advanced therapies in addition to androgen deprivation therapy (ADT) as first-line treatment for their disease as recommended by clinical practice guidelines, according to real-world data presented at the American Society of Clinical Oncology 2021 virtual annual meeting. This lack of therapeutic intensification…

Next post in Genitourinary Cancers Symposium